Povod
Reading · issue No. 2 · 23 August 2026
RUEN
Books · Close reading

A Decathlon for Your Hundredth Birthday

Peter Attia explains why normal test results promise nothing, and proposes planning health backwards from the end. A reading that also checks what the instruments he wants you to measure with actually show.

Book review · 14 min readRead the Russian original
In this issue
  1. 01The medicine that arrives late
  2. 02The four horsemen
  3. 03The metabolic root
  4. 04Planning backwards from the end
  5. 05The main lever: aerobic capacity
  6. 06The second lever: strength and muscle
  7. 07The number I do not have
  8. 08The part nobody mentions
  9. 09How this is trained in practice
  10. 10The sleep you cannot negotiate with
  11. 11Where the book sags
  12. 12What follows from it

I am forty-three, my test results are decent, and I train more than most people I know. By every familiar measure this is called “healthy”. Peter Attia spent four hundred pages explaining how little that word promises.

Attia is a surgeon by training who left oncological surgery for longevity medicine. His book Outlive came out in 2023 and became, arguably, the decade's most influential book about not falling apart.

It is thick, tedious in places, and written by a man who plainly enjoys an argument. But its central idea is worth an evening.

The medicine that arrives late

Attia divides the history of medicine into three eras. The first, before science, treated with bloodletting and prayer. The second, the one we live in, defeated infection. Antibiotics, vaccines, surgery, emergency care. We owe it the doubling of life expectancy over the past century.

The trouble is that the second medicine is built like a fire brigade. It is superb once the building is already burning. Heart attack, fracture, appendicitis.

Against the slow diseases, the ones that spend decades preparing, it is helpless, because it enters in the final act. Pre-diabetes gets diagnosed after the pancreas has been fighting for some fifteen years.3.0Attia's name for medicine that works ahead of the diagnosis: manage the risk early rather than wait for a verdict.

Hence his demand for “medicine 3.0”: stop waiting for symptoms and start managing risk in advance, on measurements rather than on how you feel. It reads like a biohacker's manifesto, but there is no zealotry in Attia. He is a man with spreadsheets, not a man selling supplements.

The four horsemen

The book then narrows its focus. Almost all of us will die of one of four things. Atherosclerosis, cancer, neurodegeneration, or metabolic dysfunction ending in type 2 diabetes. Attia calls them the four horsemen and points out an unpleasant regularity. All four creep up over decades without symptoms.

That inverts the logic of prevention. If a disease takes twenty years to prepare, then an annual check-up at forty-five is late reconnaissance, not prevention. The work has to be done while everything is fine, which is precisely why it is so hard to make yourself do it.

All four leading causes of death take decades to build and give no warning. Treatment begins at the point where the risk can no longer be managed.

The metabolic root

Attia singles out metabolic dysfunction. For him it is not merely one of the four troubles; it is the soil the other three grow in. The logic runs as follows.

Insulin resistance develops over years, dragging blood pressure, lipids and inflammation along with it, and in the end it feeds the arteries, the tumours and the brain alike. The diagnosis of diabetes arrives at the end of that road, when there is nothing left to compensate with.

The book's key point is that ordinary fasting glucose notices the problem far too late. It stays within range for as long as the pancreas can keep producing more insulin, which is to say it masks the fault until the last moment. What you want to look at is insulin, and the indices that take it into account.HOMA-IRthe insulin resistance index, calculated from fasting glucose and fasting insulin. There is no single threshold: 2.5 is a habit of American practice rather than an established value.6

From this follows a practical conclusion worth the whole chapter. In an ordinary check-up the metabolic part is measured with fasting glucose alone, that is, with the one number that slips last. The ratio of triglycerides to “good” cholesterol is calculated from the same lipid panel you are already paying for and costs nothing extra. Almost nobody looks at it.7

That ratio carries a caveat Attia does not give either: in the study where it was checked against a direct measure of insulin resistance, it predicted resistance in white adolescents and failed in African American and Hispanic ones badly enough that no threshold could be calculated for them.

One further quantity Attia asks you to watch is visceral fat, the kind that sits around the organs. It is more tightly tied to metabolic dysfunction than total weight or body mass index, and it moves faster than either.8 More precisely: it adds risk beyond body mass index rather than cancelling it. People with the same weight and the same index differ in risk by exactly how much fat sits inside the abdomen.

The good news of the chapter is that this system answers behaviour quickly. Liver enzymes sensitive to alcohol turn around in months rather than years. It is one of the few places where the effort shows up almost at once, and therefore one of the few where measuring genuinely motivates.

That is Attia's argument in its pure form. Metabolic numbers are not a sentence; they respond, and they respond fast.

Fasting glucose stays normal for exactly as long as the body can compensate. It reports the problem last, not first.

Planning backwards from the end

The book's most useful idea is not medical at all. It is an engineer's idea. Attia asks you to picture the last decade of your life and answer honestly what you want to be like in those years. Not “how long”, but “able to do what”.

Out of this comes his metaphor: the Centenarian Decathlon. Write down ten physical tasks you want to be performing in deep old age. Climb the stairs carrying a bag. Get up off the floor without using your hands. Lift a grandchild. Walk five kilometres. Open a tight jar.

Now work out what shape you need to be in today so that in forty years, having lost half of it, all of that is still available. The answer is usually sobering. To be merely getting up off the floor at eighty, you need to be noticeably stronger at forty-three than “fine”.

It is the only frame I know that makes a conversation about health concrete. “I want to be healthy” means nothing. “At eighty I want to lift fifteen kilograms to shoulder height” turns into a training plan for this week.

The main lever: aerobic capacity

Attia then does the thing the book is worth reading for. He ranks the interventions by the size of their effect. And in first place he puts neither diet nor supplements, but VO2max, the maximum rate of oxygen uptake.

The mortality gap between people in the top and bottom groups on this measure turns out to be larger than the gap between smokers and non-smokers. In the study the book leans on, the risk of death is five times higher for low fitness and one and a half times higher for smoking.1

The numbers deserve a caveat the book does not give. What was measured was treadmill workload, not oxygen uptake by gas analysis, and the cohort is clinical: 122,000 people referred for a stress test, not people off the street. The fivefold gap comes from comparing the extreme groups; the authors themselves put it more carefully and say “comparable to, if not significantly greater”.

Here the book has a weak spot it does not warn you about. Attia wants aerobic capacity measured, and most people have nothing to measure it with: the laboratory test is expensive and rare, and a watch only estimates it. My own estimate rose by about twenty per cent over six weeks this summer, and that rise coincides with two events: giving up smoking on the tenth of May, and training volume passing thirty-odd hours a month.

Checking that is easy, and the check turns out to be unpleasant. After ten days in the Pamirs my estimated aerobic capacity collapsed as though I had spent six months on the sofa. Nothing of the sort had happened: at altitude the watch accounts for oxygen on its own terms and understates the result. The collapse was an artefact of the instrument, not a loss of fitness. But if I had not known where I had been those days, I would have believed the graph.

Resting heart rate is more honest in that respect: it is measured directly rather than derived from a formula.

Resting heart rate moves slowly, and a shift of nine beats over six months is a great deal. That happens either to people who have stopped smoking or to people who have sharply increased their aerobic volume. Travel, short sleep and altitude push it back up by a few beats, and that is ordinary noise rather than a reversal.

Aerobic capacity turned out to be more strongly associated with lifespan than smoking.

The second lever: strength and muscle

Attia's second most important factor is muscle mass and strength, particularly grip strength and the ability to carry a load. The logic is simple. Sarcopenia, the age-related loss of muscle, proceeds unnoticed and ends with a person unable to rise from a chair.3 The whole Centenarian Decathlon comes down to exactly this.

And here something surfaces that the book does not discuss at all.

Two measurements on bioimpedance scales, taken eleven days apart, differed in muscle mass by precisely as much as every measurement across seven months differed.Eleven days
the gap between two readings whose spread equals the entire movement observed over seven months
Gaining or losing that much in eleven days is physically impossible. So the instrument was not measuring muscle; it was measuring water, gut contents and the conditions of the reading. Which means the whole curve a person spends six months judging his progress by lies inside its own margin of error.

I found the January pair by accident, in some papers, and it turned out to be more useful than all the other points combined. Eleven days passed between the 14th and the 25th of January, and the instrument showed a difference of 600 grams of muscle mass.

The instrument's own noise equals the entire movement across seven months, and that changes how the graph reads. The honest formulation is a different one. The changes are smaller than the instrument can resolve. The conclusion for practice is the same, but lying to yourself about half a kilo in either direction is no longer available.

For someone training thirty hours a month this is only strange at first glance. The bulk of that volume is aerobic work. Padel, walking, cycling, the elliptical. Strength work in this picture held at around two hours a month from March to June, that is, it was always present, but as short circuits.

Muscle does not grow because a person moves a lot, nor even because he occasionally picks up a kettlebell. It grows on progression: when the load increases regularly and predictably.

From which follows a conclusion inconvenient for the entire measurement industry. An instrument that cannot tell muscle from water is no good for judging your work by. It is good for exactly one thing: showing that nothing noticeable happened in six months.

The number I do not have

Attia's chapter on the heart and arteries is his most technical, and in it he proposes something fairly radical. Stop treating the familiar “bad cholesterol” as the main landmark and replace it with ApoB.

This is a protein present on exactly one particle of every atherogenic lipoprotein, which means it counts the number of particles capable of lodging in an artery wall, rather than the mass of cholesterol inside them.

The difference is not academic. It happens that the familiar numbers look respectable while the count of dangerous particles is high, and the risk is real.

Attia insists that ApoB is what should be measured, and that managing this risk should begin not at fifty-five, when the plaques are already visible, but far earlier, because the process runs for decades.

Here the book rests on solid ground. In a genetic analysis separating the contributions of different lipids, ApoB is the trait through which the whole relationship between lipids and coronary heart disease is explained, and the independent contribution of “bad cholesterol” disappears once you adjust for it.4 Reviews put it plainly: ApoB predicts risk better.5 The caveat is that the European laboratory consensus does not make ApoB the primary target and keeps it for residual risk.

An ordinary lipid panel does not include ApoB. It is not ordered by default in a public clinic or in a private laboratory's standard check-up, even though the test itself is cheap and available everywhere.

And here is the case the book was written for: the lipid panel looks reassuring, one value sits at the boundary, the doctor says “broadly normal”. A borderline value against an otherwise good profile genuinely does not decide anything on its own. The question is how many dangerous particles are in the blood, and that piece of paper does not answer it.

The practical conclusion is simple. Add ApoB to the usual lipid panel next time. The test is cheap and available in any laboratory. This is the case where one extra line on the referral gives you more than the rest of the form.

The part nobody mentions

Third on Attia's list is stability: the ability to control the body in space, to hold the spine and the foot, to breathe in the right direction.

It is the book's dullest chapter and probably its most useful. Aerobic fitness and strength are visible; stability is invisible until a disc goes or an ankle turns on a descent under a pack.

For racket sports this is particularly apt. Padel is hundreds of sharp trunk rotations in one direction, and over the years it returns the asymmetry honestly: my two sides differ in muscle by about four per cent, which is normal for a player, but it means the body has learned to work unevenly.

How this is trained in practice

Attia is fairly concrete about how to build the week, and his scheme departs from the familiar logic of “went for a run, that will do”.

The base of his pyramid is zone two: long work at a low heart rate, at which you can still talk, but with effort. That regime develops mitochondria and the ability to burn fat, and it is what builds the endurance base. Attia allots several hours a week to it and says that what matters here is volume, not heroics.

On top of that comes work at maximum output. Short intervals that raise the very VO2max in question. The classic protocol is four minutes of hard work, repeated four times. Those sixteen minutes are what move the number the book calls the most important one.2

In the original paper, though, the protocol differs in two places. The rest between intervals there is three minutes, not equal to the work, and there are three sessions a week rather than one. Four minutes of rest and once a week is already Attia's version, and it is nowhere marked as his own.

My twenty-five hours a month distribute unevenly across that frame. Padel is interval work with a ragged heart rate; walking and the elliptical sit closer to zone two; but there are no deliberate maximal intervals in the log at all.

Aerobic capacity does rise without intervals, on volume and on quitting smoking alone. But volume gives that increase once: after it the curve meets a ceiling, and only a different stimulus will move it.

The sleep you cannot negotiate with

Towards the end the book turns unexpectedly personal, and it is the rare case of an author who spent three hundred pages demanding numbers, blood work and discipline suddenly talking about things that no blood test records.

Attia admits that for years he ignored sleep, treating it as weakness, and that emotional health turned out to be his most neglected area. He describes his own therapy, his outbursts of anger, the distance from his family.

For a book about metabolism that is an abrupt change of register, and it is that part which stays in the memory longest.

His conclusion is fairly simple. You can optimise a lipid profile and still live in a way that leaves nobody wanting to be near you in that final decade. Longevity without people around it is not a prize.

Where the book sags

In fairness, Outlive has three weak places.

First. A substantial share of the recommendations rests on observational studies rather than experiments. Attia says so, but the book's overall tone is more confident than the evidence allows. The association between high VO2max and longevity is strong, but it does not prove that raising VO2max will itself extend a particular person's life.

Second. The book is written from a world where the patient can afford an annual whole-body MRI, continuous glucose monitoring and consultations with the best specialists. Much of the advice translates poorly to the reality of someone without that budget.

Third. Nutrition is its weakest chapter, and the author nearly admits as much. After a hundred pages of casting about, the conclusion amounts to this: there is no universal diet, look at your own markers. True, but thin reward for four hundred pages of waiting.

✦✦✦

What follows from it

If four hundred pages come down to three actions, they come down to these.

The aerobic base is built by volume, and built once. After that the curve meets a ceiling, the return falls, and the time cost stays where it was. At that point it is sensible to stop building it and simply hold it.

Strength work is usually the bottleneck. It is easy to substitute general activity for it: walk a lot, occasionally pick up a kettlebell. Muscle does not answer that; it answers progression. Two full strength sessions a week with the weight going up give more than another ten hours of play.

Write your own decathlon. Not an abstract “stay in shape”, but ten things you want to be able to do at eighty. It takes an evening and turns training from a habit into a plan with a purpose.

And the last thing, which seems to me the most important in the book. Attia nowhere promises immortality; he goes out of his way to avoid the question of how many years you will get.

His subject is the quality of the final decade, not its existence. That is a disciplining frame. It moves health out of the territory of anxiety and into the territory of engineering, where there are measurable parameters and comprehensible levers.

The question is not how long you will live. The question is what you will be able to do in your last ten years, and the preparation has to happen now, while everything is fine.

Next in the journal

If you are interested in how a familiar story changes once the documents are checked.

Read the related essay · All English editions

The occasion

23 August 2026

I had been meaning for a long time to read a book a week and write up what I read, because otherwise a month later nothing survives but the tone of voice. This is the first of those write-ups.

Attia sat on the shelf for six months: four hundred pages about longevity sound like an obligation rather than a book. I picked it up exactly when I had spent half a year measuring everything about myself, and the interesting question was no longer what the book advises, but whether the instruments it asks you to measure with survive being checked.

This issue was rewritten on 24 August 2026: the author's personal medical values were removed from the text. The reading of the book and the findings about instrument accuracy are unchanged.
On 31 August 2026 sources were added, and checking against them changed three statements. In the interval protocol the rest turned out to be three minutes rather than equal to the work, and the original prescribes three sessions a week rather than one. The dating “sarcopenia begins after thirty” has been removed: a quantitative review holds muscle mass almost unchanged from eighteen to sixty. The HOMA-IR threshold of 2.5 is named a habit of practice rather than an established value.

Sources

  1. 1 Mandsager K, Harb S, Cremer P, Phelan D, Nissen SE, Jaber W. “Association of Cardiorespiratory Fitness With Long-term Mortality Among Adults Undergoing Exercise Treadmill Testing”, JAMA Network Open, 19 October 2018, 1(6):e183605. Open access. 122,007 people, treadmill tests 1991–2014, median follow-up 8.4 years. Low fitness versus elite: adjusted hazard ratio 5.04 (95% CI 4.10–6.20); smoking 1.41 (1.36–1.46); diabetes 1.40; coronary artery disease 1.29. The figures were checked against the abstract in Europe PMC: the JAMA page does not release its body text to automated reading.
  2. 2 Helgerud J, Høydal K, Wang E et al. “Aerobic High-Intensity Intervals Improve VO2max More Than Moderate Training”, Medicine & Science in Sports & Exercise, 2007, 39(4):665–671. Open copy. Verbatim: “4 min of running at 90–95% HRmax followed by 3 min of active resting at 70% HRmax”, three sessions a week for eight weeks, VO2max up 7.2 per cent. The rest in the original is three minutes; four minutes of rest and one session a week appear in popularisations, Attia's included.
  3. 3 Mitchell WK, Williams J, Atherton P et al. “Sarcopenia, Dynapenia, and the Impact of Advancing Age on Human Skeletal Muscle Size and Strength: a Quantitative Review”, Frontiers in Physiology, 2012, 3:260. Open access. Median rate of loss 0.47 per cent a year in men and 0.37 in women; mass is “almost static from ages 18 to 60”. Reported ages of onset in the literature range from 27 to 60. The familiar “after thirty” goes back to a review by Paddon-Jones and Rasmussen (2009), and is not used here: its own supporting citation concerns the prevalence of sarcopenia in the elderly, not a rate of loss beginning at thirty.
  4. 4 Richardson TG, Sanderson E, Palmer TM et al. “Evaluating the relationship between circulating lipoprotein lipids and apolipoproteins with risk of coronary heart disease: A multivariable Mendelian randomisation analysis”, PLoS Medicine, 23 March 2020, 17(3):e1003062. Open access. Verbatim: “apolipoprotein B is the predominant trait that accounts for the aetiological relationship of lipoprotein lipids with risk of CHD”.
  5. 5 De Oliveira-Gomes D, Joshi PH, Peterson ED et al. “Apolipoprotein B: Bridging the Gap Between Evidence and Clinical Practice”, Circulation, 2024. Open access. Verbatim: “In epidemiologic studies, apoB outperforms LDL-C to predict ASCVD”. The counterweight: the consensus of the European Atherosclerosis Society and the Federation of Clinical Chemistry (Langlois et al., Clinical Chemistry and Laboratory Medicine, 2020, 58(4):496–517) keeps LDL cholesterol as the primary target and recommends ApoB for residual risk, chiefly where triglycerides are raised. The publisher's page for that consensus would not open; it is cited from the abstract.
  6. 6 Gayoso-Diz P, Otero-González A, Rodriguez-Alvarez MX et al. “Insulin resistance (HOMA-IR) cut-off values and the metabolic syndrome in a general adult population”, BMC Endocrine Disorders, 2013, 13:47. Open access. Formula: fasting insulin (μU/ml) × fasting glucose (mmol/l) / 22.5. Verbatim on the threshold: “There is great variability in the threshold homeostasis model assessment of insulin resistance (HOMA-IR) levels to define insulin resistance”. Two traps: the divisor 22.5 holds only for glucose in mmol/l (for mg/dl it is 405), and the insulin assay is not standardised between laboratories.
  7. 7 Giannini C, Santoro N, Caprio S et al. “The Triglyceride-to-HDL Cholesterol Ratio: Association with insulin resistance in obese youths of different ethnic backgrounds”, Diabetes Care, 2011, 34(8):1869–1874. Open access. 1,452 adolescents, with a subgroup of 146 checked by hyperinsulinaemic-euglycaemic clamp. In African American and Hispanic participants the area under the curve was not significant, so no threshold could be calculated for them.
  8. 8 Neeland IJ, Ross R, Després JP et al. “Visceral and ectopic fat, atherosclerosis, and cardiometabolic disease: a position statement”, The Lancet Diabetes & Endocrinology, 2019, 7(9):715–725. Open copy. Verbatim: “people with similar bodyweight or BMI values can have substantially different comorbidities and levels of health risk” and “above and beyond BMI”. Body mass index is called an insufficient marker, not a useless one.